Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
T-cell-engaging bispecific antibodies in cancer
NWCJ van de Donk, S Zweegman - The Lancet, 2023 - thelancet.com
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …
Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …
associated antigen and at least another one directed against an activating receptor in …
Bispecific and multispecific antibodies in oncology: opportunities and challenges
ME Goebeler, G Stuhler, R Bargou - Nature Reviews Clinical Oncology, 2024 - nature.com
Research into bispecific antibodies, which are designed to simultaneously bind two antigens
or epitopes, has advanced enormously over the past two decades. Owing to advances in …
or epitopes, has advanced enormously over the past two decades. Owing to advances in …
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet
need. Here we report the primary analysis of a phase 1b/2 trial of outpatient …
need. Here we report the primary analysis of a phase 1b/2 trial of outpatient …
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
L Tang, Z Huang, H Mei, Y Hu - Signal Transduction and Targeted …, 2023 - nature.com
The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …
understanding of both the mechanisms of immune responsiveness and immune escape …
Consensus recommendations on the management of toxicity associated with CD3× CD20 bispecific antibody therapy
JL Crombie, T Graff, L Falchi, YH Karimi, R Bannerji… - Blood, 2024 - ashpublications.org
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the
treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated …
treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated …
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Background A standard of care and optimal duration of therapy have not been established
for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was …
for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was …